Organisation paid for research Program year 2025 Source: CMS Open Payments

Chandler Clinical Trials LLC

Neither a doctor nor a teaching hospital

Research payments

$4,236,353

1,929 payments

Through program year 2025, Chandler Clinical Trials LLC is reported as receiving $4,236,353 in research payments, across 1,929 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $700,265 273
2024 Research $1,198,708 219
2023 Research $2,337,380 1,437

Breakdown

Who paid Research payments · program years 2023–2025
  1. Moderna TX, Inc. $2,938,180 1,483 payments
  2. Sumitomo Pharma America, Inc. $334,367 66 payments
  3. Sanofi US Services Inc. $305,378 55 payments
  4. Bausch Health US, LLC $290,247 213 payments
  5. Genzyme Corporation $142,996 29 payments
  6. Chiesi USA, Inc. $132,950 47 payments
  7. Alnylam Pharmaceuticals Inc. $56,621 29 payments
  8. ITI, Inc. $19,115 6 payments
  9. Pfizer Inc. $16,500 1 payment
Studies the money was for Research payments · program years 2023–2025
  1. A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $1,877,061 1,342 payments
  2. A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age $638,055 71 payments
  3. Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) $290,247 213 payments
  4. A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults $251,114 18 payments
  5. ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig $144,503 28 payments
  6. A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma $142,996 29 payments
  7. A Phase 3 Singlearm Openlabel Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids Or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $138,364 14 payments
  8. Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) $122,572 21 payments
  9. A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids Or Endometriosis $116,875 33 payments
  10. A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 $103,943 17 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record